ArticleScientific reports2020

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.

Yuqian Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.